The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib - PubMed
3 hours ago
- #ALK mutation
- #Gilteritinib
- #Drug resistance
- A novel ALK K1150dup mutation was identified in a patient with ALK-positive non-small cell lung cancer (NSCLC) who progressed on first-line lorlatinib.
- The ALK K1150dup mutation confers resistance to lorlatinib and other ALK-TKIs, including neladalkib (NVL-655), by sustaining ALK phosphorylation and downstream signaling in EML4::ALK-dependent Ba/F3 cells.
- Gilteritinib, a multi-kinase inhibitor, effectively inhibits ALK phosphorylation and suppresses proliferation in cells with the ALK K1150dup mutation, suggesting it as a potential treatment option for patients with this resistance mutation.